Navigation Links
Study finds heart failure is rare among leukemia patients on imatinib
Date:9/6/2007

HOUSTON - Congestive heart failure rarely occurs among leukemia patients who take imatinib, researchers at The University of Texas M. D. Anderson Cancer Center found after an exhaustive review of the detailed medical histories of 1,276 patients who enrolled in clinical trials for the drug.

Researchers found 22 patients, or 1.7 percent, had symptoms that could have been caused by heart failure. Of those, 18 had previous medical conditions that could also cause heart failure, such as type II diabetes, hypertension, irregular heartbeat or coronary artery disease. Six had congestive heart failure before entering treatment. The results were reported in the Aug. 15 edition of the journal Blood.

"Imatinib remains a safe drug, but monitoring patients and knowing their medical histories are always important," says Jorge Cortes, M.D., senior author of the report and professor in M. D. Anderson's Department of Leukemia. "There is no current need for routine cardiac-specific monitoring of all patients taking imatinib. However, those with significant cardiac history need to be closely monitored. Patients who develop symptoms of heart failure should be evaluated carefully and treated with standard therapy."

Of the 22 patients found to have cardiovascular conditions, 11 were able to continue on imatinib for their leukemia after dose adjustments and management of the heart failure symptoms. The standard of care for treatment includes the use of beta blockers and angiotensin converting enzyme inhibitors or angiotensin receptor blockers, notes study co-author Jean-Bernard Durand, M.D., an assistant professor in M. D. Anderson's Department of Cardiology. Both classes of drugs are approved by the FDA for treatment of heart failure and recommended by the Heart Failure Society of America.

The team also found the incidence of congestive heart failure among patients receiving imatinib to be comparable to the expected incidence in the general population as reported by the Framingham Heart Study, a defining long-term study of cardiovascular disease in the United States.

Imatinib, known by its brand name Gleevec(tm) and developed by Novartis Pharmaceuticals, is approved by the U.S. Food and Drug Administration for the treatment of chronic myelogenous leukemia (CML), Philadelphia-chromosome positive acute lymphoblastic leukemia d(ALL) and gastrointestinal stromal tumor, a rare solid tumor cancer.

Imatinib is a targeted therapy that inhibits two members of a class of enzymes called tyrosine kinases, which transmit growth and survival signals in cells. The drug also blocks a hybrid tyrosine kinase known to cause CML and Philadelphia-positive ALL.

Before the drug was developed, about only about half of CML patients survived for five years after diagnosis. The five-year survival rate of patients taking imatinib is 95 percent.

In a separate paper late last year, a research team led by scientists at the University of Pennsylvania reported that imatinib may be cardiotoxic in mammals. They found stress-induced damage to the mitochondria - the powerhouse organs in cells - in cardiac muscle of mice given the drug. They also implicated inhibition of Abl, one of the tyrosine kinases targeted by imatinib, as the molecular mechanism that causes the damage.

Additionally, 10 patients at M. D. Anderson who developed congestive heart failure after exposure to imatinib were described in the paper. The paper did not assess the frequency of heart failure among patients taking imatinib or the potential risk factors involved.

Durand, who was also a co-author on the earlier paper, says research continues to address how tyrosine kinase inhibition might affect cardiovascular risk. "We continue to work closely with oncologists to identify early biochemical markers which may predict patients at risk and implement medical therapy earlier to increase the success of tyrosine kinase inhibitors in CML patients," Durand says.


'/>"/>

Contact: Scott Merville
sdmervil@mdanderson.org
713-792-0661
University of Texas M. D. Anderson Cancer Center
Source:Eurekalert

Related medicine news :

1. Gene study links endometriosis, infertility
2. Study reveals how stress can make you sick
3. Study points out that HIV vaccine may not be accepted easily
4. A new study surpasses Gene Therapy Hurdle
5. Tomato Sauce reduces Cancer Risk- Study
6. A question on study of Adult Stem Cell
7. Study on obesity and heart failure
8. National Lung Study in the process
9. Marijuana gateway theory strengthened by study of twins
10. Old theory of adaptation confirmed by new study
11. Study casts doubt on keyboard ills
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... 13, 2017 , ... The American Board of Family Medicine's (ABFM) Board of ... Executive Officer, succeeding Dr. James C. Puffer upon his retirement. Dr. Newton will serve ... Puffer’s retirement at the end of 2018. Upon assuming the role of President and ...
(Date:10/13/2017)... ... 13, 2017 , ... PurhealthRX , a leading Health and Nutrition Company, ... Purzorb™process to full spectrum CBD oil will revolutionize the rapidly growing CBD market by ... be easily incorporated into liquid products, while reducing costs to end users. , The ...
(Date:10/13/2017)... , ... October 13, 2017 , ... Lori R. Somekh, ... member of ElderCounsel, a national organization of elder law and special needs planning attorneys. ... and rules. It also provides a forum to network with elder law attorneys nationwide,” ...
(Date:10/13/2017)... OBISPO, Calif. (PRWEB) , ... October 13, 2017 , ... ... or dementia. However, many long-term care insurance companies have a waiver for care if ... the 90-day elimination period, when the family pays for care, is often waived, so ...
(Date:10/13/2017)... New York, NY (PRWEB) , ... October 13, 2017 , ... ... most influential people in business to advocate for action towards gender equality at their ... 18,000 views from around the globe, and reached a social audience of over 3 ...
Breaking Medicine News(10 mins):
(Date:9/25/2017)... 25, 2017  EpiVax, Inc., a leader in ... immune-engineering today announced the launch of EpiVax Oncology ... personalized therapeutic cancer vaccines. EpiVax has provided $500,000 ... to enabling technologies to the new precision immunotherapy ... EpiVax Oncology as Chief Executive Officer. Gad brings ...
(Date:9/19/2017)... Ky. , Sept. 19, 2017   ZirMed Inc ... predictive analytics, today announced that it has been ranked #1 ... Black Book™ Rankings 2017 User Survey. ZirMed was ... solution for large hospitals and medical centers over 200 beds ... Black Book,s healthcare technology user survey history. ...
(Date:9/12/2017)... Sept. 12, 2017  Consumer reviews on the independent review site ... the number one company for hearing aids, ranking it higher than ... brands. ... #1 by Consumers For Hearing Aids ... Hearing is an online store that provides high performance, state-of-the-art, German-engineered ...
Breaking Medicine Technology: